Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

ARCH.V Relative to the S&P 500

ARCH.V Relative to the Sector

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Arch Biopartners Inc (TSXV:ARCH.V) seasonal charts above shows that a Buy Date of March 2 and a Sell Date of May 24 has resulted in a geometric average return of 14.49% above the benchmark rate of the S&P 500 Total Return Index over the past 7 years. This seasonal timeframe has shown positive results compared to the benchmark in 6 of those periods. This is a very good rate of success, but the return underperforms the relative buy-and-hold performance of the stock over the past 7 years by an average of 7.65% per year.

The seasonal timeframe is Inline with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

A word of caution: Only 7 years of data is available for shares of ARCH.V, perhaps insufficient to create a seasonal profile that accurately gauges the seasonal tendencies influencing the investment. Ideally, while 20 years is preferred, at least 10 years of data is required to perform a seasonal analysis that is considered to be reliable for future seasonal periods.

Arch Biopartners Inc is a clinical stage company developing technologies with the potential to make medical or commercial impacts. The company is developing a drug platform Metablok to produce drug candidates to inhibit organ inflammation caused via the DPEP-1 pathway. Its under development portfolio is AB569, a potential new treatment for antibiotic resistant bacterial infections in the lungs or wounds; and, Borg peptide coatings that increase corrosion resistance and decrease bacterial biofilm on various medical grade metals and plastics.

To download ARCH.V seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: ARCH.V